First Responders: SARS-CoV-2 and the Immune System

Angela Rasmussen and Ya-Chi Ho explore the positive and negative aspects of the host immune response to SARS-CoV-2 infection and discuss how this knowledge influences therapeutic benefits.

The Scientist Creative Services Team
Oct 29, 2020

FREE Webinar

Friday, November 20, 2020
2:30 - 4:00 PM, Eastern Standard Time

Register Now

The immune system fights SARS-CoV-2 infection, but it also causes serious clinical symptoms when it rages out of control. In this webinar from The Scientist, Angela Rasmussen and Ya-Chi Ho will discuss how the immune system reacts to SARS-CoV-2, whether these responses are beneficial or deleterious, and the mechanisms by which immune responses determine COVID-19 severity and patient outcomes.

Topics to be covered

  • The nature of the host response to SARS-CoV-2
  • Understanding adaptive immune responses to SARS-CoV-2 using high-dimensional single-cell profiling

Register Now

Meet the Speakers:

Angela Rasmussen, PhD
Center for Global Health Science and Security
Georgetown University

Ya-Chi Ho, MD, PhD
Assistant Professor
Department of Microbial Pathogenesis
Yale School of Medicine

November 2020

Death on the shore

Researchers investigate recent gray whale strandings along North America’s Pacific coast


Sponsored Product Updates

Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today announced the availability of an important new research tool for the sequencing and surveillance of COVID-19.
The Rise of Cannabis Extraction Labs
Scientists in cannabis extraction laboratories are bravely pioneering a new field of agro-chemical engineering.
Expanding Cell Growth Capabilities
Download this eBook to learn how to optimize large-scale cell growth using culture shakers, incubators, and bioreactors!
SynDevRx Announces Positive Data from Phase 1 Safety Trial of SDX-7320 in Late Stage Cancer Patients
SynDevRx has submitted to the FDA results from a Phase 1 dose escalation study in patients with metastatic and progressing solid tumors to assess the safety and tolerability of SDX-7320. Additional outcome measures suggest that SDX-7320 may slow the rate of disease progression and formation of new metastases. Exploratory endpoints suggest that SDX-7320 may induce favorable changes to insulin and insulin resistance and other key metabolic hormones (leptin, adiponectin) as well as to multiple angiogenic biomarkers.